LB Pharmaceuticals Inc (LBRX)
LB Pharmaceuticals is a New York drug developer focused on LB-102, a candidate for schizophrenia and mood disorders. It last closed at $40.30 on Nov 17, down 6.26% on the day. The average 12-month price target from 5 analysts is $61.60 (+52.9% from the last close), with a high of $80.00 and a low of $35.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (4 buy, 1 hold, 0 sell).
Key Stats
Last 12 monthsNot reported for this period.
From LBRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 5 analysts who set a price target on LBRX in the past 90 days. The average target is $61.60, with a high of $80.00 and a low of $35.00, compared with the last close of $40.30.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 9 | Canaccord Genuity | Initiated | Buy | $65 |
| Oct 6 | Guggenheim | Initiated | Buy | $80 |
| Oct 5 | Roth Capital | Downgrade | Hold | $35 |
| Oct 2 | Needham | Initiated | Buy | $68 |
| Aug 24 | HC Wainwright & Co. | Target raised | Buy | $45 → $60 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 16% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 48). The nearest support is the 50 day average at $39.88, and the nearest resistance the 100 day average at $40.37.
| RSI (14) | 48.20 | Middle of its range | Neutral |
| MACD | 0.97 | Above its signal line | Bullish |
| Stochastic | 51.2 | Middle of its range | Neutral |
| ADX (14) | 25.6 | Trending down | |
| Williams %R | -71.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 0.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −0.1% | Change over 10 sessions | Bearish |
| ATR (14) | $2.69 | Typical daily range, 6.7% of price |
| RSI (14) | 55.52 | Middle of its range | Neutral |
| MACD | 2.50 | Below its signal line | Bearish |
| Stochastic | 50.8 | Middle of its range | Neutral |
| ADX (14) | 28.6 | Trending up | |
| Williams %R | -57.9 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 3.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −9.7% | Change over 10 sessions | Bearish |
| ATR (14) | $4.43 | Typical daily range, 11.0% of price |
What happened before
See how LBRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90DNo whale options trades in LBRX in the last 90 days.
LBRX Institutional Ownership
Full report →- ▲99 buying vs 40 selling
- ▲Held by funds +10.2 pts
- ▲Funds holding +32
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 147 | 115 | +27.8% |
| In funds' top 10 | 7 | 5 | +40.0% |
| Held by funds | 105.4% | 95.2% | +10.2 pts |
| New / increased | 42 / 57 | 41 / 42 | +19.3% |
| Reduced / sold out | 29 / 11 | 13 / 3 | +150.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LBRX is in one of them and how their past LBRX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LBRX in an article yet. Here's the latest on the wider market.
About LB Pharmaceuticals
LB Pharmaceuticals is a biopharmaceutical company based in New York that develops treatments for neuropsychiatric disorders. Its main product candidate, LB-102, is in late-stage testing for schizophrenia and bipolar depression, with a planned study in major depressive disorder as a supplemental treatment. LB-102 is a chemical relative of amisulpride, an antipsychotic already used in many countries outside the United States. The company aims to offer its treatments to patients and to the psychiatrists who prescribe for them.
- Headquarters
- New York, NY


